Glioblastoma

Indexed in Crossref

66 abstracts matching glioblastoma from the meeting's journal supplement, fetched live from Crossref 2026-11-12 10:09 UTC. This is a keyword search, not the complete abstract book.

• E14053
  Outcomes of patients with glioblastoma multiforme (GBM) with lymphopenia.

  Muhammad Areeb Ashfaq, Muhammad Dawood Amir Sheikh, Sakteesh Gurunathan, Daisy E. Escobar
• E14066
  Characterization of toxicities associated with sulfamethoxazole/trimethoprim (TMP-SMX) for pneumocystis jirovecii prophylaxis in patients with glioblastoma (GBM).

  Elizabeth Carter Cordell, Ryan Kasper, Stephen Bagley, Desiree Croteau
• 2077
  INB-200: Phase I study and characterization of gene-modified autologous gamma delta (γδ) T cells in newly diagnosed glioblastoma multiforme (GBM).

  Louis B. Nabors, Kate Rochlin, Mina Lobbous, Antonio Di Stasi et al.
• TPS2095
  CLARITY-GBM: A phase II, multi-centered, open-label, single-arm study to evaluate the safety and efficacy of cetuximab and lomustine (CCNU) in adult patients with recurrent high-grade glioblastoma.

  Zoya Peelay, Kritika Mehrotra, Atanu Bhattacharjee, Nandini Sharrel Menon et al.
• E14079
  Response in first-in-human chemotherapy-free combination immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): Nogapendekin alfa inbakicept (NAI) and PD-L1 t-haNK plus bevacizumab (BEV).

  Simon Khagi, Jose Arganda Carrillo, David J. Park, Courtney Lewis et al.
• 2059
  Rituximab pre-conditioning in a phase I study of CARv3-TEAM-E for recurrent glioblastoma (GBM): The INCIPIENT trial.

  Bryan D. Choi, Elizabeth R. Gerstner, William T. Curry, Deborah Anne Forst et al.
• 2013
  Updated overall survival, safety, and neurologic function outcomes from a phase 1 trial of bivalent chimeric antigen receptor (CAR) T cell therapy in recurrent glioblastoma (GBM).

  Erin E. Hollander, Arati Suvas Desai, Amy Marshall, Kelly Shipman et al.
• TPS2101
  Progress report of a phase 2 study of BPM31510 (a lipid nano dispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy.

  Seema Nagpal, Brian R. Stocksdale, Adam Louis Cohen, Andrew J. Brenner et al.
• E14005
  Multimodal diffusion on low-rank approximation radiomic phenotypes with deep learning survival model for prediction of survival in post-operative GBM patients.

  Roy Nasr, Bardia Rodd
• 12095
  Protective factors supporting caregiver well-being in glioblastoma.

  Desiree Reinken, Sean Reed
• E14078
  Epimedin A to prevent glioblastoma growth and invasion.

  Erick Zecena, Michael Mildner, Kota Ramana
• E14052
  SEER-based projections of U.S. meningioma and glioblastoma incidence and survival through 2050.

  Mobin Mobadersani
• 2079
  Lucicebtide (ST101) plus chemoradiation in newly diagnosed GBM patients: Efficacy, pharmacodynamics, and safety from phase 2 window-of-opportunity study.

  Fabio M. Iwamoto, Osama Al Dalahmah, Robin Arthur Buerki, Franco Abbate et al.
• E14074
  Clinical characterization of patients with molecular glioblastoma.

  Sofia Danzo, Emily A. Sloan, Byram H. Ozer, Edina Komlodi-Pasztor
• E14099
  AI-based volumetric vs bidimensional RANO 2.0 progression assessment: Prognostic value for overall survival in glioblastoma.

  Seok Yeong (Gene) Kim, Michael J. Ciesielski
• 1514
  Use of a patient-facing digital tool for glioblastoma outside scheduled clinic visits.

  Jason Binder, Akanksha Sharma, Danielle Ralic, Soma Sengupta
• 2084
  Transcriptomic signature of temozolomide treatment-effect heterogeneity in IDH-wildtype glioblastoma.

  Amirhossein Zare, Seyed Reza Salarikia, Amirhesam Zare, Mohammad Kashkooli et al.
• E14091
  Intratumoral heterogeneity and genetic testing utilization in glioblastoma patients: A retrospective study at the University of Vermont Medical Center.

  Leena Ziane, Shrey Patel, Oluwatosin Akintola
• E14068
  Discovery of novel biomarkers for glioblastoma using VHH antibodies.

  Mitsuaki Shirahata, Ryota Maeda, Masayoshi Fukuoka, Takuro Ehara et al.
• E14087
  Tumor treating fields in newly diagnosed glioblastoma: An updated systematic review and meta-analysis with geographic subgroup analysis.

  Manaswini Krishnakumar, Arankesh Mahadevan, Aayushi Pareek, Hariharan Eswaran et al.
• E14055
  Real-world comparative outcomes of including levetiracetam with standard treatment in glioblastoma multiforme: A multi-center retrospective cohort study.

  Shreyas Shirodkar, Farzeen Fatma Syed, Jennifer Collins, Amir Kamran
• E14062
  Safety and efficacy of B7H3/IL13Rα2 bispecific armored CAR-T for treatment of recurrent/refractory glioblastoma.

  Shuyu Zheng, Qi Zhu, Xiaobo Yu, Yan Chen et al.
• E15099
  A rationally designed local delivery platform (OncoPLEX) for sustained docetaxel release to overcome therapeutic barriers in post-resection solid tumors and glioblastoma.

  Raanan Berger, Meidan Dvir, Noam Emanuel
• 12097
  Assessing loneliness in glioblastoma patients and caregivers using a nationwide survey.

  Jacob Ellen, Quinn T. Ostrom, Fabio M. Iwamoto, Lakshmi Nayak et al.
• E14100
  Local delivery of SN-38 using a biodegradable implantable membrane for treatment of glioblastoma.

  Lucas Krauel, Ann-Kathrin Gruber, Ester Lopera, Anna Huguet et al.
• E14038
  The prognostic impact of epilepsy in glioblastoma: Insights from a systematic review and meta-analysis.

  Amrat Ayaz Ali, ShriMahalakshmi Bollakpalli, Louissa Cidral, Tania Rodriguez Garcia et al.
• 2056
  Development of human B7H3/IL13Ra2 bispecific armored CAR-T for treatment of glioblastoma.

  Keming Zhang, Ning Jiang, Charles Zhao, Weijun Sha et al.
• E14041
  Communication of tumor testing and molecular results to patients and caregivers in glioblastoma: A national survey.

  David Robles, Quinn T. Ostrom, Fabio M. Iwamoto, Lakshmi Nayak et al.
• E14065
  Cumulative barriers to access: An AI-driven analysis of eligibility restrictions, clinical setting, and molecular gatekeeping in 509 interventional glioblastoma trials (2016-2025).

  Andrew Ng, Sudeep Kumar Siddappa Malleshappa, Wilson C. Mertens
• 2045
  Beyond survival: Longitudinal prognostication in glioblastoma using conditional survival—A population-based study.

  Obuli Srinivasan Gurunathan, Owais Gul, Fawad Talat, Saagarika Sundaram Venkatesan et al.
• 2066
  Mapping the exhausted and tolerized myeloid populations in the glioblastoma tumor microenvironment.

  Yu-Ting Tsai, Jamie Sagastume, Jian-Ying Chuang, Tsung-I Hsu et al.
• 2070
  Phase I trial to evaluate the safety and tolerability of fb-PMT in patients with recurrent glioblastoma.

  Nicholas Alfred Blondin, Sylvia Christine Kurz, Zachary Corbin, Joachim M. Baehring et al.
• 2554
  Single-cell multi-omics and TCR sequencing to identify early tumor cavity homing and phenotypic evolution of CAR-T cells in glioblastoma.

  Qi Zhu, Shuyu Zheng, Xiaobo Yu, Yan Chen et al.
• E14103
  Peak inflammatory stress versus baseline neutrophil-to-lymphocyte ratio (NLR) for prediction of in-hospital mortality in critically ill glioblastoma patients: MIMIC-IV cohort analysis.

  Ummul Zohra Asfeen, Mohammad Aquib, Md Zaryab Ahmad, Moayad Ahmed
• 2047
  Interrupting HEG1/Cx43 interaction to promote cuproptosis via inhibiting gap junction to overcome glioblastoma radioresistance.

  Lanlan Guo, Haoyue Hu, Mingying Xiao, Wei Chen et al.
• E14071
  GZMK+ T cells in glioblastoma and an activated, non-exhausted phenotype.

  Agnese Losurdo, Alberto Susana, Angelo Dipasquale, Pasquale Persico et al.
• 2081
  Decision support for treatment of patients with glioblastoma: A systems biology approach enabled by explainable AI.

  Thomas D. Brown, Serdar Turkarslan, Christopher Uhl, Yu He et al.
• 2044
  Tumor treating fields therapy in patients with newly diagnosed glioblastoma and poor performance status: Real-world analysis of patients treated in the US.

  Omar H. Butt, Dina Daitchman, Yair Horesh, Ori Farber et al.
• TPS2098
  Randomized phase 2 study to evaluate the efficacy and safety of silevertinib in combination with temozolomide in newly diagnosed patients with EGFRvIII-positive IDHwt MGMT unmethylated glioblastoma.

  Patrick Y. Wen, Fabio M. Iwamoto, Rupesh Kotecha, Sergey Yurasov et al.
• TPS2097
  Resection and intracranial implant of (Z)- n -butylidenephthalide wafer followed by temozolomide as treatment for recurrent glioblastoma: A randomized phase IIb/III trial.

  Clark C. Chen, David Liu, Jui-Hao Lee, Chia-Liang Tai et al.
• TPS2096
  TTFields with maintenance temozolomide (TMZ) and pembrolizumab versus TTFields with maintenance TMZ and placebo for newly diagnosed glioblastoma: The phase 3 EF-41/KEYNOTE D58 trial.

  David D. Tran, Ashley Parham Ghiaseddin, Michael Lim, Michael Weller et al.
• 2042
  Initial analysis of adoptive neoantigen-specific T-cell immunotherapy for MGMT-unmethylated glioblastoma (TVI-AST-008): Signals amid control arm attrition.

  Tolga Tuncer, Patrick Thomas Grogan, Michael E. Salacz, Michael Badruddoja et al.
• 2062
  An alternative approach to limiting surgical and radiation stress in patients with glioblastoma.

  Eduard E. Rostorguev, Alla Ivanovna Shikhlyarova, Elena M. Frantsiyants, Galina V. Zhukova et al.
• E13777
  Prognostic associations of the G8 geriatric screening tool in the EORTC Brain Tumor Group trials 1608 and 1709 in patients with newly diagnosed glioblastoma.

  Michael Weller, Luc Boone, Patrick Roth, Matthias Preusser et al.
• E14075
  Characterization and clinical impact of temozolomide-induced hepatotoxicity in IDH -wild type glioblastoma: A comprehensive analysis of injury patterns, CTCAE grade transitions, and survival outcomes.

  Gözde Savaş, Sumeyye Zehra Erol, Imdat Eroglu, Sıla Soylu Koçoğlu et al.
• TPS2102
  Gliofocus: A global, open-label, randomized phase 3 study comparing niraparib with temozolomide in newly diagnosed MGMT-unmethylated glioblastoma.

  Nader Sanai, Shwetal Mehta, Artak Tovmasyan, Jocelyn Harmon et al.
• E14089
  Localized (Z)- n -butylidenephthalide biodegradable wafer as surgical adjuvant in recurrent glioblastoma for extending survival and re-sensitizing chemotherapy: A compassionate use study.

  Clark C. Chen, Jen-Wei Tsai, Jui-Hao Lee, David Liu et al.
• TPS2105
  BRIDGES: A phase 3 randomized trial of immediate postoperative cesium-131 tile-based radiation therapy followed by abbreviated chemoradiation for newly diagnosed glioblastoma (NCT07195591).

  Clark C. Chen, Rohil Shekher, Brijal Desai, Andrew Kopecky et al.
• 2078
  Regorafenib in recurrent glioblastoma: Real-world outcomes from a Colombian cohort (REGOMA-COL).

  Javier Jacobo, Juan Esteban Garcia-Robledo, Adriana Aya, Jorge Aristizabal et al.
• 3019
  Discovery from single-cell RNA sequencing profiles of 18 CPTAC glioblastoma patients and validation in bulk profiles of 138 TCGA patients and two human-derived cell lines of a whole-transcriptome predictor of overall survival and drug targets by using quantum mechanics–based AI/ML.

  Orly Alter, David B. Oberman, Daniel Shabtai, Jessica W. Tsai et al.
• 2071
  Suicide gene therapy for recurrent glioblastoma using allogeneic bone marrow–derived mesenchymal stem cell gene delivery (MSC/CD): A first-in-human, dose-escalation phase I clinical trial.

  Jaejoon Lim, JeongMin Sim, Ju-Won Kim, Sojung Hwang et al.
• TPS2094
  Randomized phase 2 trial of ruxolitinib in combination with radiation and temozolomide compared to radiation and temozolomide for newly diagnosed glioblastoma.

  Manmeet Singh Ahluwalia, Rupesh Kotecha, Zouina Sarfraz, Vyshak Venur et al.
• 2050
  Caregiver professional employment and its impact on glioblastoma patient survival: Results from two prospective studies.

  Vincenzo Di Nunno, Alicia Tosoni, Isacco Desideri, Maria Michiara et al.
• 2068
  Identification of prognostically relevant residual tumor burden in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs [ 18 F]FET PET.

  Jens Blobner, Katharina Müller, Michael Muether, Wolfgang Roll et al.
• 2049
  Histopathology-verified comparison of FET PET and contrast-enhanced MRI for tumor visualization in glioblastoma.

  Roman Stuerzl, Sabrina Viktoria Kirchleitner, Julia Lorenz, Katharina Müller et al.
• 2015
  Azeliragon, a RAGE inhibitor, plus temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Final results from a dose-finding phase in the CAN-201 NDG trial.

  Maria Martinez Garcia, Manuel Valiente, Juan Manuel Sepulveda, Estela Pineda et al.
• 2065
  A phase 2 double-blind, randomized, prospective, placebo-controlled study of NanO₂ combined with radiation and temozolomide in patients with newly diagnosed glioblastoma: RESTORE.

  Samuel A. Goldlust, Michael A. Badruddoja, Nicholas Alfred Blondin, Katherine B. Peters et al.
• 2016
  Change in relative cerebral blood volume as a biomarker for early response to bevacizumab in patients with recurrent glioblastoma: ECOG-ACRIN EAF151.

  Jerrold L. Boxerman, Bradley S. Snyder, Kathleen M. Schmainda, Maciej Mrugala et al.
• 2076
  Pooled analysis of phase I and expanded access study cohorts of DOC1021 (dubodencel) in combination with chemoradiation for glioblastoma.

  Jay-Jiguang Zhu, Sigmund H. Hsu, Yoshua Esquenazi, Rodrick C. Zvavanjanja et al.
• 2004
  MAGMA: Multi-arm glioblastoma Australasia phase 3 trial.

  Craig Gedye, Katharine Ellen Cuff, Peter Kar Han Lau, Anthony J. Dowling et al.
• 2063
  Management of first recurrence from IDH-wildtype glioblastoma with re-resection or stereotactic radiosurgery: A retrospective, international, multicenter study.

  Nico Teske, Antonio Dono, Ajay Niranjan, Jacob S. Young et al.
• 2006
  A personalized neoantigen vaccine to reprogram the immune landscape of glioblastoma.

  Jack Y. Ghannam, Daniel Kovarsky, Laine Marrah, Landon Oetjen et al.
• TPS2106
  Prospective, randomized, placebo-controlled phase 2b trial of SurVaxM plus adjuvant temozolomide in newly diagnosed glioblastoma (SURVIVE).

  Manmeet Singh Ahluwalia, David A. Reardon, Nicholas A. Butowski, Robert Aiken et al.
• 3020
  Quantum mechanics-based multi-tensor AI/ML as predictor of patients' overall survival, gene targets, and drug responses from their glioblastoma tumors' whole genomes.

  Orly Alter, Sri Priya Ponnapalli, Marissa Coppola, Angela C. Gushue et al.
• 2001
  A multicenter randomized phase III study for newly diagnosed, maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide versus chemoradiotherapy alone: Japan Clinical Oncology Group study JCOG1703 (MACS study).

  Ryuta Saito, Toshihiro Kumabe, Junki Mizusawa, Yuya Ishikawa et al.
• 2011
  Outcomes of a feasibility and safety trial of tile-based radiation therapy with cesium-131 followed by external beam radiation therapy with concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma (NCT05342883).

  Clark C. Chen, Kris Smith, Lindsey Sloan, Adam W. Nowlan et al.